Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
FinanceWire - WSW, NY, September 25th, 2026, FinanceWire
Three months ago, Nuvectis Pharma (NASDAQ: NVCT) was an oncology developer anchored by a single early-stage program. Today it holds ex-China rights to the world’s first approved once-daily oral Factor B inhibitor and, as of this morning, to a breakthrough-designated cancer drug. NXP200, the company’s oral, brain-penetrant BRAF inhibitor, has been granted Breakthrough Therapy Designation for BRAF V600-mutant, recurrent or progressive high-grade glioma, an aggressive brain cancer with few effective options once it returns.
The designation, granted by China’s Center for Drug Evaluation to Nuvectis’s partner Haisco Pharmaceutical Group, is reserved for drugs treating serious conditions where early data point to a meaningful advantage over existing therapy, and it brings closer regulator guidance and potentially a faster review once an application is filed. It follows a completed dose-escalation study in which the drug, on its own,
%3Amax_bytes(150000)%3Astrip_icc()%2FGettyImages-2295904524-5af3a3fdb2d34b5391e8304afb4e7749.jpg&w=3840&q=75)
%3Amax_bytes(150000)%3Astrip_icc()%2FGettyImages-2296213970-9079820ab2fc43aaa54163c49d0b63fc.jpg&w=3840&q=75)
